Expanding Production Capacity for High Producing mAb Processes

Parrish Galliher (life science innovator, consultant w/BDO) and moderator Ben Locwin (executive, Black Diamond Networks) discuss how a large, well-established biotech company with an expanding pipeline addressed the technology and process requirements to support the necessary increase in production capacit

Raw Material Delay Derails PPQ Causing 2-Year Process Delay

Ron Bates (vice president, development and manufacturing, Immunovant) and Ben Locwin (executive, Black Diamond Networks) discuss how a small biotech small company with a low-demand Fc fusion protein identified, where addressed, and how then implemented a strategy to overcome PPQ failu

Overcoming Materials Supply Challenges

Mark Petrich (vice president, technical operations, Krystal Biotech) and Ben Locwin (executive, Black Diamond Networks) discuss how material supply challenges can impact every biotech, large or small, equally - you either have what you need or you don't. However, there are proactive strategies your company can implement to avoid or reduce delays caused by supply bottlenecks.

Selecting the Right Facility Design/Tech to Support AAV Production/Scale

Dave Backer (chief commercial officer, Oxford Biomedica) and moderator Ben Locwin (executive, Black Diamond Networks) discuss the stark technology and process similarities and differences between cell/gene therapies and mAbs and the lessons that can be applied to accelerate AAV production and scale.

Tech Options to Improve Low-Producing Biotherapeutic Processes

Parrish Galliher (independent industry consultant) and Ben Locwin (executive, Black Diamond Networks) discuss how a small biotech start-up leveraged technology to accelerate production to compete with large biotech in the race to the clinic.

CGT - Bridging the Technology Gap

Dave Backer (chief commercial officer, Oxford Biomedica) and moderator Ben Locwin (executive Black Diamond Networks) discuss how the diversified and complex CGT market, currently in fed batch mode, is eyeing perfusion (where appropriate) is also experimenting with dedicated up/downstream technologies to improve recovery rates.

Pharma Shifts to Biologics Closing Remarks